Published in Proc Natl Acad Sci U S A on January 11, 2010
Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet (2011) 2.51
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18
Current status of genome-wide association studies in cancer. Hum Genet (2011) 2.14
Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet (2011) 1.54
Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk. Carcinogenesis (2011) 1.37
Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.28
Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev (2010) 1.21
Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. Prostate (2010) 1.20
Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res (2010) 1.19
Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res (Phila) (2011) 1.17
Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers? Genome Med (2010) 1.09
Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.08
Evaluating genetic risk for prostate cancer among Japanese and Latinos. Cancer Epidemiol Biomarkers Prev (2012) 1.08
Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk. J Urol (2010) 1.08
Two susceptibility loci identified for prostate cancer aggressiveness. Nat Commun (2015) 1.06
Multiplexed electrochemical protein detection and translation to personalized cancer diagnostics. Anal Chem (2013) 1.01
Evaluation of reported prostate cancer risk-associated SNPs from genome-wide association studies of various racial populations in Chinese men. Prostate (2013) 1.00
Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Hum Genet (2015) 0.95
Prognostic and predictive biomarkers: tools in personalized oncology. Mol Diagn Ther (2014) 0.92
Nuclear morphometry, nucleomics and prostate cancer progression. Asian J Androl (2012) 0.86
Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses. Prostate (2011) 0.85
Genome-wide two-locus epistasis scans in prostate cancer using two European populations. Hum Genet (2012) 0.84
Genome-wide copy-number variation analysis identifies common genetic variants at 20p13 associated with aggressiveness of prostate cancer. Carcinogenesis (2011) 0.82
Number of prostate cancer risk alleles may identify possibly 'insignificant' disease. BJU Int (2010) 0.82
A genome-wide search for loci interacting with known prostate cancer risk-associated genetic variants. Carcinogenesis (2012) 0.82
Whole-exome sequencing of over 4100 men of African ancestry and prostate cancer risk. Hum Mol Genet (2015) 0.81
Utility of genome-wide association study findings: prostate cancer as a translational research paradigm. J Intern Med (2012) 0.81
Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC). J Cancer (2013) 0.80
Inherited susceptibility for aggressive prostate cancer. Asian J Androl (2012) 0.79
Genome-wide association studies on prostate cancer: the end or the beginning? Protein Cell (2013) 0.79
Fine-mapping of prostate cancer aggressiveness loci on chromosome 7q22-35. Prostate (2010) 0.78
Genetics of asthma susceptibility and severity. Clin Chest Med (2012) 0.78
A Family History of Lethal Prostate Cancer and Risk of Aggressive Prostate Cancer in Patients Undergoing Radical Prostatectomy. Sci Rep (2015) 0.77
Impact of genotyping on outcome of prostatic biopsies: a multicenter prospective study. Mol Med (2011) 0.77
The identification of trans-associations between prostate cancer GWAS SNPs and RNA expression differences in tumor-adjacent stroma. Oncotarget (2015) 0.76
Using graded response model for the prediction of prostate cancer risk. Hum Genet (2012) 0.76
Replication study of 34 common SNPs associated with prostate cancer in the Romanian population. J Cell Mol Med (2016) 0.75
Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy. PLoS One (2015) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007) 14.37
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol (2005) 12.31
Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A (2006) 10.32
Genetic risk prediction--are we there yet? N Engl J Med (2009) 7.30
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet (2009) 5.06
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet (2009) 3.94
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Functions of heparan sulfate proteoglycans in cell signaling during development. Development (2004) 3.56
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev (2008) 3.05
Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst (2009) 2.84
Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res (2009) 2.27
Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol (2008) 2.17
Prostate cancer genomics: towards a new understanding. Nat Rev Genet (2008) 2.08
Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate (2009) 1.95
Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol (2007) 1.93
Familial concordance in cancer survival: a Swedish population-based study. Lancet Oncol (2007) 1.90
Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet (2009) 1.90
Two independent prostate cancer risk-associated Loci at 11q13. Cancer Epidemiol Biomarkers Prev (2009) 1.78
8q24 and prostate cancer: association with advanced disease and meta-analysis. Eur J Hum Genet (2008) 1.72
Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet (2006) 1.70
Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features. Clin Cancer Res (2009) 1.49
A novel prostate cancer susceptibility locus at 19q13. Cancer Res (2009) 1.49
Complexities of prostate-cancer risk. N Engl J Med (2008) 1.30
Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles. J Urol (2008) 1.27
Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev (2009) 1.24
Staging prostate cancer. Microsc Res Tech (2000) 1.20
Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy. Hum Pathol (2009) 0.99
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Resolving individuals contributing trace amounts of DNA to highly complex mixtures using high-density SNP genotyping microarrays. PLoS Genet (2008) 20.38
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (2008) 7.14
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med (2014) 6.89
Quality of life after radical prostatectomy or watchful waiting. N Engl J Med (2002) 6.83
The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature (2011) 6.71
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Prostate cancer. N Engl J Med (2003) 5.91
Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation (2007) 5.87
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell (2002) 5.23
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47
Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol Cell Biol (2002) 4.27
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer (2004) 4.10
Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol (2012) 4.07
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet (2002) 3.87
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet (2008) 3.79
Recent developments in genomewide association scans: a workshop summary and review. Am J Hum Genet (2005) 3.76
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet (2011) 3.73
Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell (2002) 3.71
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One (2011) 3.59
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst (2007) 3.26
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem (2007) 3.24
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol (2004) 3.21